IL15 and neoplasm: In vivo, mice bearing syngeneic 4T1 tumors had significant tumor regression and increased survival following treatment with the combination of LIVP-IL15-RFP and LIVP-IL15Ra-RFP, lymphocytes were recruited to tumor sites, and no harmful effects were observed in the liver or spleen (40).